CLYM

SEC source: 0001415889-24-018708 · form4-07022024_010700.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 2,479,872

F1 · price: Received in exchange for equity of Tenet Medicines, Inc. ("Tenet") pursuant to an Agreement and Plan of Merger and Reorganization, dated April 10, 2024, by and among the Issuer, Tango Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Tango Merger Sub") and Tenet (the "Acquisition Agreement"). Under the terms of the Acquisition Agreement, on June 27, 2024, Tenet was acquired by the Issuer through the merged of Tango Merger Sub with and into Tenet (the "Acquisition"), with Tenet surviving the Acquisition as a wholly-owned subsidiary of the Issuer.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

F4 · ownership.nature: These securities are held directly by Sera.

SEC source: 0001415889-24-018708 · form4-07022024_010700.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

RA Capital Nexus Fund III, L.P. · CIK 0001883840 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 11,572,586

F1 · price: Received in exchange for equity of Tenet Medicines, Inc. ("Tenet") pursuant to an Agreement and Plan of Merger and Reorganization, dated April 10, 2024, by and among the Issuer, Tango Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Tango Merger Sub") and Tenet (the "Acquisition Agreement"). Under the terms of the Acquisition Agreement, on June 27, 2024, Tenet was acquired by the Issuer through the merged of Tango Merger Sub with and into Tenet (the "Acquisition"), with Tenet surviving the Acquisition as a wholly-owned subsidiary of the Issuer.

F2 · ownership.nature: These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund").

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus II Fund, L.P. (the "Nexus Fund II"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Fund and the Nexus Fund III collectively own approximately 81% of the outstanding equity interests of Sera Medicines, LLC ("Sera"). Accordingly, each of the Fund, the Nexus Fund III and the Adviser may be deemed to beneficially own the securities held by Sera. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.

SEC source: 0001415889-24-018467 · form4-06282024_090644.xml · derivative · entry 1

Dunn Judith · CIK 0001811904 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-25

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001415889-24-018483 · form4-06282024_100608.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-25

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's continuous service through such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.

F3 · ownership.nature: Dr. Andrew Levin is a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors. Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II, and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001415889-24-018461 · form4-06282024_090603.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-25

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001415889-24-018481 · form4-06282024_100647.xml · derivative · entry 1

Levin Andrew David · CIK 0001867539 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-25

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

SEC source: 0001415889-24-018469 · form4-06282024_090606.xml · derivative · entry 1

Rosenberg Adam Joseph · CIK 0001867407 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-25

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001415889-24-018463 · form4-06282024_090603.xml · derivative · entry 1

Tate Simon · CIK 0001867441 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-25

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001415889-24-017799 · form4-06212024_060656.xml · nonDerivative · entry 2

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,755

F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.

SEC source: 0001415889-24-017799 · form4-06212024_060656.xml · derivative · entry 3

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

F4 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

SEC source: 0001415889-24-017799 · form4-06212024_060656.xml · nonDerivative · entry 1

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

SEC source: 0001415889-24-010516 · form4-04082024_090450.xml · derivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,046

Underlying: Common Stock · 17,847 shares

Expires 2031-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of February 26, 2021 (the "February 2021 Vesting Commencement Date") and 1/48thof the total number of shares each monthly anniversary of the February 2021 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the February 2021Vesting Commencement Date.

SEC source: 0001415889-24-010516 · form4-04082024_090450.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 505,307

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-008754 · form4-03202024_080318.xml · derivative · entry 1

Pimblett Emily · CIK 0001969365 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

F2 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of 1/8th of the total number of shares on the three-month anniversary of March 18, 2024 (the "March 2024 Vesting Commencement Date") and 1/8th of the total number of shares each three-month anniversary of the March 2024 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the two-year anniversary of the March 2024 Vesting Commencement Date.

SEC source: 0001415889-24-006211 · form4-03042024_040348.xml · derivative · entry 4

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,893

Underlying: Common Stock · 15,297 shares

Expires 2031-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of February 26, 2021 (the "February 2021 Vesting Commencement Date") and 1/48thof the total number of shares each monthly anniversary of the February 2021 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the February 2021Vesting Commencement Date.

SEC source: 0001415889-24-006211 · form4-03042024_040348.xml · derivative · entry 3

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,431 shares

Expires 2030-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of April 1, 2019 (the "April 2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the April 2019 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the April 2019 Vesting Commencement Date.

SEC source: 0001415889-24-006211 · form4-03042024_040348.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 487,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-006211 · form4-03042024_040348.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D AND CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 472,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-031527 · doc4.xml · derivative · entry 1

Dunn Judith · CIK 0001811904 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001104659-23-063233 · tm2316475-1_4seq1.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's, a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors, continuous service through such date.

F1 · ownership.nature: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin's, a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors, continuous service through such date.

F2 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F3 · ownership.nature: Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001209191-23-031535 · doc4.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-23-031540 · doc4.xml · derivative · entry 1

Tate Simon · CIK 0001867441 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-23-031518 · doc4.xml · derivative · entry 2

Rosenberg Adam Joseph · CIK 0001867407 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-23-031509 · doc4.xml · derivative · entry 1

Levin Andrew David · CIK 0001867539 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2033-05-17

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

SEC source: 0001209191-23-018531 · doc4.xml · derivative · entry 4

Morisset Valerie · CIK 0001868517 · EVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,190

Underlying: Common Stock · 61,191 shares

Expires 2031-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of February 26, 2021 (the "February 2021 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the February 2021 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the February 2021 Vesting Commencement Date.

SEC source: 0001209191-23-018531 · doc4.xml · derivative · entry 3

Morisset Valerie · CIK 0001868517 · EVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,431

Underlying: Common Stock · 255,219 shares

Expires 2030-02-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of 12/48ths of the total number of shares on the one-year anniversary of April 1, 2019 (the "April 2019 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the April 2019 Vesting Commencement Date thereafter (or if there is no corresponding day, on the last day of the month) for so long as the Reporting Person remains an officer, director, employee, consultant and/or advisor of the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the April 2019 Vesting Commencement Date.

SEC source: 0001209191-23-018531 · doc4.xml · nonDerivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 466,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-018531 · doc4.xml · nonDerivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-055404 · doc4.xml · derivative · entry 1

Lavelle Erin · CIK 0001737613 · COO & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2032-10-30

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.

SEC source: 0001209191-22-055407 · doc4.xml · derivative · entry 1

Azelby Robert · CIK 0001656998 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2032-10-30

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.

SEC source: 0001209191-22-055400 · doc4.xml · derivative · entry 1

Bucher James B · CIK 0001664928 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2032-10-30

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.

SEC source: 0001209191-22-055412 · doc4.xml · derivative · entry 2

Morisset Valerie · CIK 0001868517 · EVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2032-10-30

F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of October 31, 2022 (the "2022 Vesting Commencement Date") for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2022 Vesting Commencement Date.

SEC source: 0001209191-22-033206 · doc4.xml · derivative · entry 1

Dunn Judith · CIK 0001811904 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-22-033217 · doc4.xml · derivative · entry 1

PATTERSON LEONE D · CIK 0001233539 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001104659-22-067196 · tm2217502-1_4seq1.xml · derivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F2 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin, a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors, continuous service through such date.

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F2 · ownership.nature: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to Dr. Andrew Levin, a Partner and Managing Director of the Adviser who serves on the Issuer's board of directors, continuous service through such date.

F3 · ownership.nature: Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund, the Nexus Fund, the Nexus Fund II and the Account. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

SEC source: 0001209191-22-033220 · doc4.xml · derivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-22-033223 · doc4.xml · derivative · entry 1

Tate Simon · CIK 0001867441 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-22-033214 · doc4.xml · derivative · entry 2

Rosenberg Adam Joseph · CIK 0001867407 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

SEC source: 0001209191-22-033210 · doc4.xml · derivative · entry 1

Levin Andrew David · CIK 0001867539 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2032-05-18

F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

SEC source: 0001209191-22-005659 · doc4.xml · derivative · entry 1

Lavelle Erin · CIK 0001737613 · COO & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2032-01-26

F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022.

SEC source: 0001209191-22-005647 · doc4.xml · derivative · entry 1

Azelby Robert · CIK 0001656998 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Common Stock · 500,000 shares

Expires 2032-01-26

F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022.

SEC source: 0001209191-22-005630 · doc4.xml · derivative · entry 1

Bucher James B · CIK 0001664928 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires 2032-01-26

F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022.

SEC source: 0001209191-22-005639 · doc4.xml · derivative · entry 1

Morisset Valerie · CIK 0001868517 · EVP, R&D and CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2032-01-26

F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/48th of the shares will vest on each monthly anniversary of January 27, 2022.

SEC source: 0001209191-21-051627 · doc4.xml · derivative · entry 4

AI ETI LLC · CIK 0001871741 · 10% owner

Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner

ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner

Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 641,025 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F1 · kind: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F2 · ownership.direct: The securities reported are held directly by AI ETI LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI ETI LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

SEC source: 0001209191-21-051627 · doc4.xml · derivative · entry 3

AI ETI LLC · CIK 0001871741 · 10% owner

Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner

ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner

Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,568,375 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F1 · kind: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F1 · derivative.exercise_date: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F1 · derivative.expiration_date: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F2 · ownership.direct: The securities reported are held directly by AI ETI LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI ETI LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

SEC source: 0001209191-21-051627 · doc4.xml · nonDerivative · entry 2

AI ETI LLC · CIK 0001871741 · 10% owner

Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner

ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner

Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,009,400

F3 · shares: Represents securities purchased in the Issuer's initial public offering.

F2 · ownership.direct: The securities reported are held directly by AI ETI LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI ETI LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

SEC source: 0001209191-21-051627 · doc4.xml · nonDerivative · entry 1

AI ETI LLC · CIK 0001871741 · 10% owner

Access Industries Holdings LLC · CIK 0001391297 · Affiliate of 10% Owner

ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · Affiliate of 10% Owner

Blavatnik Len · CIK 0001326628 · Affiliate of 10% Owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,209,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Each share of Series A Redeemable Convertible Preferred Stock and Series B Redeemable Convertible Preferred Stock was automatically converted into one share of common stock upon the completion of Eliem Therapeutics, Inc.'s (the "Issuer") initial public offering and had no expiration date.

F2 · ownership.direct: The securities reported are held directly by AI ETI LLC and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because AIH indirectly controls all of the outstanding voting interests in AI ETI LLC, AIM controls AIH and Mr. Blavatnik controls AIM and holds a majority of the outstanding voting interests in AIH. AIH, AIM and Mr. Blavatnik each disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

SEC source: 0001104659-21-106405 · tm2125234-1_4.xml · derivative · entry 14

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 139,481 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.exercise_date: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.expiration_date: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F6 · derivative.underlying_shares: These securities are held directly by the Account.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F6 · ownership.nature: These securities are held directly by the Account.

SEC source: 0001104659-21-106405 · tm2125234-1_4.xml · derivative · entry 13

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 485,493 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.exercise_date: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.expiration_date: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F6 · derivative.underlying_shares: These securities are held directly by the Account.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F6 · ownership.nature: These securities are held directly by the Account.

SEC source: 0001104659-21-106405 · tm2125234-1_4.xml · derivative · entry 12

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

RA Capital Nexus Fund, L.P. · CIK 0001780117 · Director · 10% owner

RA Capital Nexus Fund II, L.P. · CIK 0001825376 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 288,461 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.exercise_date: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F1 · derivative.expiration_date: On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

F5 · derivative.underlying_shares: These securities are held directly by the Nexus Fund II.

F3 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

F5 · ownership.nature: These securities are held directly by the Nexus Fund II.